Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Antiviral Res. 2020 Jul;179:104811. doi: 10.1016/j.antiviral.2020.104811. Epub 2020 Apr 29.
There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.
目前迫切需要确定能够抑制 COVID-19 大流行的抗病毒药物。在此，我们报告了 SARS-CoV-2 对重组人干扰素 α 和 β（IFNα/β）的敏感性。在 Vero 细胞中，浓度为每毫升 50 国际单位（IU）的 IFN-α 或 IFN-β 处理分别使病毒滴度降低 3.4 对数或超过 4 对数。IFN-α 和 IFN-β 处理的 EC 分别为 1.35 IU/ml 和 0.76 IU/ml。这些结果表明，SARS-CoV-2 比包括 SARS-CoV 在内的许多其他人类致病病毒更为敏感。总的来说，我们的结果表明，I 型人干扰素在抑制 SARS-CoV-2 感染方面具有潜在的疗效，这一发现可能为 COVID-19 的未来治疗选择提供信息。
